{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T18:17:09Z","timestamp":1769883429408,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00259-025-07519-1","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:52:08Z","timestamp":1756083128000},"page":"1469-1478","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Radioligand treatment with [177Lu]Lu-PSMA I&amp;T in elderly Patients - Safety, efficacy, and prognostic factors for survival"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3267-6323","authenticated-orcid":false,"given":"Marcel","family":"Schwinger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charis","family":"Kalogirou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Scheper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximiliane","family":"D\u00e4uwel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Katharina","family":"Seitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert","family":"K\u00fcbler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas K.","family":"Buck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp E.","family":"Hartrampf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"issue":"3","key":"7519_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"23","key":"7519_CR2","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1200\/JCO.19.00928","volume":"37","author":"JL Mohler","year":"2019","unstructured":"Mohler JL, Armstrong AJ. Management of prostate cancer: current treatment options and future perspectives. J Clin Oncol. 2019;37(23):1845\u201352. https:\/\/doi.org\/10.1200\/JCO.19.00928.","journal-title":"J Clin Oncol"},{"issue":"2","key":"7519_CR3","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/jamaoncol.2015.5570","volume":"2","author":"HI Scher","year":"2016","unstructured":"Scher HI, et al. Castration-resistant prostate cancer: new biomarkers for evaluation and treatment. JAMA Oncol. 2016;2(2):234\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2015.5570.","journal-title":"JAMA Oncol"},{"issue":"13","key":"7519_CR4","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1158\/1078-0432.CCR-19-1226","volume":"26","author":"AJ Armstrong","year":"2020","unstructured":"Armstrong AJ, et al. Prostate cancer: challenges in diagnosis and management. Clin Cancer Res. 2020;26(13):3233\u201344. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1226.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"7519_CR5","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"issue":"10276","key":"7519_CR6","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797\u2013804. https:\/\/doi.org\/10.1016\/S0140-6736(21)00237-3.","journal-title":"Lancet"},{"issue":"10459","key":"7519_CR7","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024;404(10459):1227\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(24)01653-2.","journal-title":"Lancet"},{"issue":"5","key":"7519_CR8","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.eururo.2017.02.013","volume":"71","author":"A Rosenthal","year":"2017","unstructured":"Rosenthal A, et al. Radioligand therapy with [\u00b9\u2077\u2077Lu]Lu-PSMA I&T: mechanisms of action and clinical implications. Eur Urol. 2017;71(5):782\u201391. https:\/\/doi.org\/10.1016\/j.eururo.2017.02.013.","journal-title":"Eur Urol"},{"issue":"9","key":"7519_CR9","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1200\/JCO.19.02247","volume":"38","author":"ST Tagawa","year":"2020","unstructured":"Tagawa ST, et al. Targeting PSMA in prostate cancer: clinical implications of radioligand therapy. J Clin Oncol. 2020;38(9):992\u20139. https:\/\/doi.org\/10.1200\/JCO.19.02247.","journal-title":"J Clin Oncol"},{"issue":"5","key":"7519_CR10","doi-asserted-by":"publisher","first-page":"788","DOI":"10.2967\/jnumed.116.179745","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, et al. Theranostic radioligand therapy with [\u00b9\u2077\u2077Lu]Lu-PSMA I&T for prostate cancer: results of the first clinical trial. J Nucl Med. 2016;57(5):788\u201395. https:\/\/doi.org\/10.2967\/jnumed.116.179745.","journal-title":"J Nucl Med"},{"issue":"3","key":"7519_CR11","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00259-020-05146-z","volume":"48","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, et al. Safety and efficacy of [\u00b9\u2077\u2077Lu]Lu-PSMA I&T for prostate cancer: results of a prospective trial. Eur J Nucl Med Mol Imaging. 2021;48(3):751\u201360. https:\/\/doi.org\/10.1007\/s00259-020-05146-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"7519_CR12","doi-asserted-by":"publisher","first-page":"588","DOI":"10.2967\/jnumed.121.262635","volume":"63","author":"A Gafita","year":"2022","unstructured":"Gafita A, et al. Radioligand therapy in prostate cancer: adverse events and management strategies. J Nucl Med. 2022;63(4):588\u201395. https:\/\/doi.org\/10.2967\/jnumed.121.262635.","journal-title":"J Nucl Med"},{"issue":"4","key":"7519_CR13","doi-asserted-by":"publisher","first-page":"654","DOI":"10.2967\/jnumed.123.266702","volume":"65","author":"J Ferdinandus","year":"2024","unstructured":"Ferdinandus J, et al. Prognostic factors and clinical outcomes of [\u00b9\u2077\u2077Lu]Lu-PSMA I&T in elderly patients with mCRPC. J Nucl Med. 2024;65(4):654\u201361. https:\/\/doi.org\/10.2967\/jnumed.123.266702.","journal-title":"J Nucl Med"},{"key":"7519_CR14","doi-asserted-by":"publisher","unstructured":"Weber S, Seitz AK, K\u00fcbler H, Kosmala A, Buck AK, Werner RA, et al. Radioligandentherapie Mit Lu-177-PSMA I&T Bei \u00e4lteren Menschen \u2013 Sicherheit, wirksamkeit und prognostische Faktoren f\u00fcr Das \u00fcberleben. Nuklearmedizin. 2024;63(49). https:\/\/doi.org\/10.1055\/s-0044-1782376.","DOI":"10.1055\/s-0044-1782376"},{"issue":"8","key":"7519_CR15","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.2967\/jnumed.122.265259","volume":"64","author":"R Tauber","year":"2023","unstructured":"Tauber R, Knorr K, Retz M, Rauscher I, Grigorascu S, Hansen K, D\u2019Alessandria C, Wester HJ, Gschwend J, Weber W, Eiber M, Langbein T. Safety and efficacy of [\u00b9\u2077\u2077Lu]-PSMA-I&T radioligand therapy in octogenarians with metastatic castration-resistant prostate cancer: report on 80 patients over the age of 80 years. J Nucl Med. 2023;64(8):1244\u201351. https:\/\/doi.org\/10.2967\/jnumed.122.265259.","journal-title":"J Nucl Med"},{"issue":"8","key":"7519_CR16","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","volume":"22","author":"J Ferdinandus","year":"2021","unstructured":"Ferdinandus J, Violet J, Sandhu S, et al. Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol. 2021;22(8):1115\u201325. https:\/\/doi.org\/10.1016\/S1470-2045(21)00274-6.","journal-title":"Lancet Oncol"},{"issue":"12","key":"7519_CR17","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.2967\/jnumed.120.242057","volume":"61","author":"R Seifert","year":"2020","unstructured":"Seifert R, Herrmann K, Kleesiek J, Sch\u00e4fers M, Shah V, Xu Z, et al. Semiautomatically quantified tumor volume using 68Ga-PSMA-11 PET as a biomarker for survival in patients with advanced prostate cancer. J Nucl Med. 2020;61(12):1786\u201392. https:\/\/doi.org\/10.2967\/jnumed.120.242057.","journal-title":"J Nucl Med"},{"issue":"1","key":"7519_CR18","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s00259-023-06281-6","volume":"50","author":"PE Hartrampf","year":"2023","unstructured":"Hartrampf PE, Weinzierl FX, Serfling SE, Schirbel A, Seitz AK, Buck AK, et al. SUVmean on baseline [18F]PSMA-1007 PET and clinical parameters predict overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA I&T. Eur J Nucl Med Mol Imaging. 2023;50(1):56\u201367. https:\/\/doi.org\/10.1007\/s00259-023-06281-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"7519_CR19","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.2967\/jnumed.117.193581","volume":"58","author":"S Schmuck","year":"2017","unstructured":"Schmuck S, von Klot CA, Henkenberens C, Sohns JM, Christiansen H, Wester HJ, et al. Initial experience with volumetric 68Ga-PSMA I&T PET\/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with prostate cancer. J Nucl Med. 2017;58(12):1962\u20138. https:\/\/doi.org\/10.2967\/jnumed.117.193581.","journal-title":"J Nucl Med"},{"issue":"11","key":"7519_CR20","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.2967\/jnumed.121.263072","volume":"63","author":"A Gafita","year":"2022","unstructured":"Gafita A, Rauscher I, Weber M, et al. Novel framework for treatment response evaluation using PSMA PET\/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. J Nucl Med. 2022;63(11):1651\u20138. https:\/\/doi.org\/10.2967\/jnumed.121.263072.","journal-title":"J Nucl Med"},{"issue":"12","key":"7519_CR21","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34(12):1402\u201318. https:\/\/doi.org\/10.1200\/JCO.2015.64.2702.","journal-title":"J Clin Oncol"},{"issue":"12","key":"7519_CR22","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1007\/s00259-022-05845-2","volume":"49","author":"PE Hartrampf","year":"2022","unstructured":"Hartrampf PE, Seitz AK, Weinzierl FX, Serfling SE, Schirbel A, Rowe SP, et al. Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [\u00b9\u2077\u2077Lu]Lu-PSMA I&T during long-term follow-up. Eur J Nucl Med Mol Imaging. 2022;49(12):4262\u201370. https:\/\/doi.org\/10.1007\/s00259-022-05845-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"7519_CR23","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13550-024-01143-0","volume":"14","author":"A Karimzadeh","year":"2024","unstructured":"Karimzadeh A, Hecker CS, Knorr K, Heck MM, D\u2019Alessandria C, Weber WA, et al. Matched-pair analysis of mCRPC patients receiving 177Lu-labeled PSMA-targeted radioligand therapy in a 4-week versus 6-week treatment interval. EJNMMI Res. 2024;14(1):94. https:\/\/doi.org\/10.1186\/s13550-024-01143-0.","journal-title":"EJNMMI Res"},{"issue":"6","key":"7519_CR24","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","volume":"19","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19(6):825\u201333. https:\/\/doi.org\/10.1016\/S1470-2045(18)30198-0.","journal-title":"Lancet Oncol"},{"issue":"1","key":"7519_CR25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2967\/jnumed.123.265986","volume":"65","author":"L Steinhelfer","year":"2024","unstructured":"Steinhelfer L, Lunger L, Cala L, Pfob CH, Lapa C, Hartrampf PE, et al. Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy. J Nucl Med. 2024;65(1):79\u201384.","journal-title":"J Nucl Med"},{"issue":"1","key":"7519_CR26","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s00259-023-06281-6","volume":"50","author":"PE Hartrampf","year":"2023","unstructured":"Hartrampf PE, Seitz AK, Weinzierl FX, Serfling SE, Schirbel A, Rowe SP, et al. SUVmean on baseline [18F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu]Lu-PSMA I&T. Eur J Nucl Med Mol Imaging. 2023;50(1):56\u201367. https:\/\/doi.org\/10.1007\/s00259-023-06281-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"7519_CR27","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","volume":"22","author":"A Gafita","year":"2022","unstructured":"Gafita A, Calais J, Grogan TR, Hadaschik BA, Wang H, Weber M, et al. Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol. 2022;22(8):1115\u201325. https:\/\/doi.org\/10.1016\/S1470-2045(21)00274-6.","journal-title":"Lancet Oncol"},{"issue":"11","key":"7519_CR28","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.2967\/jnumed.121.263072","volume":"63","author":"A Gafita","year":"2022","unstructured":"Gafita A, Calais J, Grogan TR, Hadaschik BA, Wang H, Weber M, et al. Novel framework for treatment response evaluation using PSMA PET\/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. J Nucl Med. 2022;63(11):1651\u20138. https:\/\/doi.org\/10.2967\/jnumed.121.263072.","journal-title":"J Nucl Med"},{"issue":"12","key":"7519_CR29","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34(12):1402\u201318. https:\/\/doi.org\/10.1200\/JCO.2015.64.2702.","journal-title":"J Clin Oncol"},{"issue":"2","key":"7519_CR30","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.euf.2024.04.012","volume":"11","author":"M Wenzel","year":"2025","unstructured":"Wenzel M, Preisser F, Humke C, Hoeh B, Mandel P, Haferkamp A, Babst C, et al. Frailty and comorbidity burden as independent prognostic factors in metastatic hormone-sensitive and castration-resistant prostate cancer: results from a multicenter cohort study. Eur Urol Focus. 2025;11(2):234\u201342. https:\/\/doi.org\/10.1016\/j.euf.2024.04.012.","journal-title":"Eur Urol Focus"},{"issue":"8","key":"7519_CR31","doi-asserted-by":"publisher","first-page":"e3831","DOI":"10.1016\/j.urolonc.2023.06.013","volume":"41","author":"PS Deol","year":"2023","unstructured":"Deol PS, Shi Y, Iyer RB, Sharma P, Crawford ED, Freedland SJ. The impact of frailty on mortality in men with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide. Urol Oncol. 2023;41(8):e3831\u20137. https:\/\/doi.org\/10.1016\/j.urolonc.2023.06.013.","journal-title":"Urol Oncol"},{"issue":"64","key":"7519_CR32","doi-asserted-by":"publisher","first-page":"108415","DOI":"10.18632\/oncotarget.21600","volume":"8","author":"K Rahbar","year":"2017","unstructured":"Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Sch\u00e4fers M, Essler M, Baum RP. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. Oncotarget. 2017;8(64):108415\u201323. https:\/\/doi.org\/10.18632\/oncotarget.21600.","journal-title":"Oncotarget"},{"issue":"5","key":"7519_CR33","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1007\/s00259-021-05590-3","volume":"49","author":"J Ferdinandus","year":"2022","unstructured":"Ferdinandus J, Violet J, Sandhu S, et al. PSA response and overall survival in men with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA radioligand therapy. Eur J Nucl Med Mol Imaging. 2022;49(5):1594\u2013604. https:\/\/doi.org\/10.1007\/s00259-021-05590-3.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07519-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07519-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07519-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:43:07Z","timestamp":1769834587000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07519-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7519"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07519-1","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"assertion":[{"value":"23 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol was reviewed and approved by the Ethics Committee of the University of W\u00fcrzburg; approval number: 20220502 01; date of decision: October 10, 2022. Written informed consent from the participants was not required for this retrospective study in accordance with local\/national guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent statement Informed consent was obtained from all subjects involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}